AlphaQuest LLC Sells 29,653 Shares of Organon & Co. (NYSE:OGN)

AlphaQuest LLC trimmed its stake in Organon & Co. (NYSE:OGN - Free Report) by 76.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,288 shares of the company's stock after selling 29,653 shares during the period. AlphaQuest LLC's holdings in Organon & Co. were worth $139,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Prospera Private Wealth LLC bought a new position in shares of Organon & Co. in the third quarter worth approximately $25,000. Horizon Bancorp Inc. IN increased its position in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after purchasing an additional 1,585 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after purchasing an additional 1,734 shares during the last quarter. Riverview Trust Co grew its position in Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock valued at $36,000 after acquiring an additional 1,292 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock valued at $41,000 after acquiring an additional 1,324 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Trading Down 1.7 %

OGN stock traded down $0.27 on Friday, reaching $15.33. The company's stock had a trading volume of 20,159,277 shares, compared to its average volume of 2,411,726. The business has a fifty day simple moving average of $15.45 and a two-hundred day simple moving average of $16.54. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The firm has a market cap of $3.95 billion, a PE ratio of 4.60, a PEG ratio of 0.90 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Remove Ads

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.57 billion. As a group, research analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.31%. Organon & Co.'s dividend payout ratio (DPR) is 33.63%.

Wall Street Analyst Weigh In

A number of research analysts have commented on OGN shares. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Morgan Stanley reduced their price target on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, February 14th. Finally, Barclays reduced their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Organon & Co. currently has a consensus rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.